The role of the purinergic P2X7 receptor in inflammation

被引：209
作者：
Lister M.F. [1 ]
Sharkey J. [2 ]
Sawatzky D.A. [1 ]
Hodgkiss J.P. [2 ]
Davidson D.J. [1 ]
Rossi A.G. [1 ]
Finlayson K. [2 ]
机构：
[1] MRC Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ
[2] Astellas CNS Research in Edinburgh, Chancellor's Building, University of Edinburgh, EH16 4SB
来源：
Journal of Inflammation | / 4卷 / 1期
基金：
英国医学研究理事会;
关键词：
P2X7 Receptor; Infected Macrophage; P2X7R Activation; P2X7R Expression; P2X7R Antagonist;
D O I：
10.1186/1476-9255-4-5
中图分类号：
学科分类号：
摘要：
The inflammatory process, orchestrated against a variety of injurious stimuli, is composed of three inter-related phases; initiation, propagation and resolution. Understanding the interplay between these three phases and harnessing the beneficial properties of inflammation whilst preventing its damaging effects, will undoubtedly lead to the advent of much needed therapies, particularly in chronic disease states. The P2X7 receptor (P2X 7R) is increasingly recognised as an important cell surface regulator of several key inflammatory molecules including IL-1β, IL-18, TNF-α and IL-6. Moreover, as P2X7R-dependent cytokine production is driven by activating the inflammasome, antagonists of this receptor are likely to have therapeutic potential as novel anti-inflammatory therapies. The function of the P2X7R in inflammation, immunity and its potential role in disease will be reviewed and discussed. © 2007 Lister et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 150 条
[1]  
Nathan C., Points of control in inflammation, Nature, 420, pp. 846-852, (2002)
[2]  
Gilroy D.W., Lawrence T., Perretti M., Rossi A.G., Inflammatory resolution: New opportunities for drug discovery, Nat Rev Drug Discov, 3, pp. 401-416, (2004)
[3]  
Collo G., Neidhart S., Kawashima E., Kosco-Vilbois M., North R.A., Buell G., Tissue distribution of the P2X7 receptor, Neuropharmacology, 36, pp. 1277-1283, (1997)
[4]  
Abbracchio M.P., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., Miras-Portugal M.T., King B.F., Gachet C., Jacobson K.A., Weisman G.A., Burnstock G., Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family, Trends in Pharmacological Sciences, 24, pp. 52-55, (2003)
[5]  
North R.A., Molecular Physiology of P2X Receptors, Physiol Rev, 82, pp. 1013-1067, (2002)
[6]  
Burnstock G., Purinergic signalling - An overview, Novartis Found Symp, 276, pp. 26-48, (2006)
[7]  
Di Virgilio F., The P2Z purinoceptor: An intriguing role in immunity, inflammation and cell death, Immunology Today, 16, pp. 524-528, (1995)
[8]  
Falzoni S., Munerati M., Ferrari D., Spisani S., Moretti S., Di Virgilio F., The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role, J Clin Invest, 95, pp. 1207-1216, (1995)
[9]  
MacKenzie A.B., Young M.T., Adinolfi E., Surprenant A., Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors, J Biol Chem, 280, pp. 33968-33976, (2005)
[10]  
Hodgkiss J.P., McLuckie J., Sharkey J., Finlaysonk K., Characterisation of intracellular calcium responses in HEK293 cells stably expressing human P2X receptors., 4th International Symposium of Nucleosides and Nucleotides, 38, (2004)
12345678910